NCT05441410 - Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Malaria

Interventions

DRUG

Pyronaridine Tetraphosphate, Artesunate Drug Combination

Combination drug for treatment of uncomplicated malaria

BIOLOGICAL

PfSPZ Challenge (NF54)

cryopreserved Plasmodium falciparum sporozoites injected by intravenous inoculation

BIOLOGICAL

MVA ME-TRAP

virally vectored subunit vaccine candidates where ME-TRAP is expressed by the non-replicating viral vector Modified Vaccinia Ankara (MVA)

BIOLOGICAL

ChAd63 ME-TRAP

virally vectored subunit vaccine candidates where ME-TRAP is expressed by the non-replicating viral vector Chimpanzee Adenovirus 63 (ChAd63)

BIOLOGICAL

Sodium chloride (NaCl) 0.9%

0.9% NaCl solution for injection

All Listed Sponsors

collaborator

Sanaria Inc.

INDUSTRY

collaborator

University of Oxford

OTHER

lead

University Hospital Tuebingen

OTHER